What the changes say
- Option Care Health expanded its risk disclosures by consolidating several operational items into new, comprehensive risk factors covering competition, compounding regulations, debt, acquisitions, and AI.
- Financial figures were updated, including an increase to the share repurchase program authorization up to $1 billion and total outstanding borrowings reaching $1,176.3 million.
What changed since the prior 10-K
New
- New
Increasing competition from established and vertically integrated healthcare providers, coupled with industry consolidation and cost pressures, may limit our ability to grow revenue, maintain pricing, secure favorable contracts, and access critical pharmaceutical products
Heightened competition from vertically integrated healthcare providers and pharmaceutical wholesalers could limit revenue growth, pricing power, and contract access.
- New
Ongoing reimbursement rate reductions, pricing pressures from Third-Party Payers and managed care payers, and increasing payer consolidation could significantly impact revenue, reduce profitability, and concentrate financial dependence on a few large payers
Ongoing reimbursement rate cuts and payer consolidation threaten revenue and increase financial dependence on a few large managed care payers.
- New
Regulatory changes, increased scrutiny, or reclassification of our compounding practices as an FDA-regulated outsourcing facility could lead to costly compliance requirements, operational disruptions, and reputational harm
Regulatory reclassification of compounding practices as an FDA-regulated outsourcing facility could trigger costly compliance mandates under the Drug Quality & Security Act.
- New
We may incur additional debt, which could increase the risks associated with our leverage
Future incurrence of additional secured debt could exacerbate leverage-related risks and financial constraints.
- NewRisks Relating to Our Common Stock
Pursuing acquisitions or strategic investments and alliances may expose us to integration challenges, valuation uncertainties, operational disruptions, and potential financial losses if these investments fail to deliver expected benefits
Pursuing business acquisitions and strategic investments exposes the company to valuation uncertainties, integration challenges, and potential financial losses.
- NewRisks Relating to Our Common Stock
Reliance on third-party hosting services exposes us to potential security breaches, service disruptions, and pricing changes that could negatively impact operations and financial performance
Reliance on third-party hosting services and the deployment of AI technologies introduce cybersecurity, compliance, litigation, and regulatory liabilities.
Dropped
- Dropped
The healthcare industry is highly competitive
- Dropped
Failure to develop new services or adapt to changes and trends within the healthcare industry may adversely affect our business
- Dropped
We are subject to pricing pressures and other risks involved with Third-Party Payers
- Dropped
We cannot predict the impact of changing requirements on compounding pharmacies
General healthcare industry competition.
- DroppedRisks Relating to Our Indebtedness
Despite our indebtedness, we may still incur significantly more debt, which could exacerbate the risks associated with our substantial leverage
- DroppedRisks Relating to Our Common Stock
We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our common stock, which could depress the price of our common stock
- DroppedRisks Relating to Our Common Stock
Acquisitions, strategic investments and strategic relationships involve certain risks
- DroppedRisks Relating to Our Common Stock
Our business is dependent on the services provided by third-party information technology vendors
- DroppedRisks Relating to Our Common Stock
We use, and may continue to expand our use of, machine learning and artificial intelligence (“AI”) technologies to deliver our services and operate our business
Reworded
- 98% rewritten
Changes in industry pricing benchmarks could adversely affect our financial performance
Expanded to explicitly mention commercial payers, PBMs, Medicaid programs, WAC, and ASP alongside AWP benchmarks.
- 63% rewritten
Introduction of new drugs, accelerated adoption of existing lower margin drugs or withdrawal of existing drugs could adversely affect our revenues and profitability when prescribers prescribe these drugs for their patients or they are mandated by Third-Party Payers
Text maintained largely identical while updating context around drug pipelines and price competition.
- 51% rewrittenRisks Relating to Our Common Stock
We cannot guarantee that our stock repurchase program will enhance long-term stockholder value
Updated to reflect the Board's January 2026 increase of the share repurchase program authorization from $500 million to $1 billion.
Was: We cannot guarantee that our stock repurchase program will be fully implemented or that it will enhance long-term stockholder value
- 45% rewritten
Delays in reimbursement may adversely affect our liquidity, cash flows and results of operations
Reiterated complex reimbursement processes and collection challenges without altering core text.
- 27% rewritten
Our existing indebtedness could adversely affect our business and growth prospects
Updated outstanding borrowings figures as of December 31, 2025, to $1,176.3 million, including $676.3 million under the First Lien Term Loan.
- 23% rewritten
Changes in our relationships with pharmaceutical manufacturers, including changes in drug availability or pricing, could adversely affect our business and financial results
Added a new sentence noting that some pharmaceutical manufacturers attempt to limit the number of preferred distributors for their products.
Was: Changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing, could adversely affect our business and financial results
All 32 risk factors
Headings as the filing states them, in filing order.
Other
- 01Company-Specific Risk Factors
- 02Our revenue and profitability could decline if the pharmaceutical industry undergoes certain changes, including limiting or discontinuing research, development, production and marketing of the pharmaceuticals that are compatible with the services we provide
- 03If we lose relationships with managed care organizations (“MCOs”) and other non-governmental third-party payers, we could lose access to a significant number of patients and our revenue and profitability could decline
- 04Increasing competition from established and vertically integrated healthcare providers, coupled with industry consolidation and cost pressures, may limit our ability to grow revenue, maintain pricing, secure favorable contracts, and access critical pharmaceutical productsNew
- 05If we are unable to maintain relationships with existing patient referral sources, our business and consolidated financial condition, results of operations, and cash flows could be materially adversely affected
- 06Changes in industry pricing benchmarks could adversely affect our financial performance98% rewritten
- 07Changes in our relationships with pharmaceutical manufacturers, including changes in drug availability or pricing, could adversely affect our business and financial results23% rewritten
- 08A disruption in pharmaceutical and medical supply could adversely impact our business
- 09A shortage of qualified registered nursing staff, pharmacists and other professionals could adversely affect our ability to attract, train and retain qualified personnel and could increase operating costs
- 10Introduction of new drugs, accelerated adoption of existing lower margin drugs or withdrawal of existing drugs could adversely affect our revenues and profitability when prescribers prescribe these drugs for their patients or they are mandated by Third-Party Payers63% rewritten
- 11Changes in future business conditions could cause business investments and/or recorded goodwill to become impaired, and our results of operations could suffer if there is an impairment of goodwill
- 12A significant change in, or noncompliance with, governmental regulations and other legal requirements could have a material adverse effect on our reputation and profitability
- 13Federal actions and legislation could reduce reimbursement rates from governmental payers and adversely affect our results of operations
- 14Delays in reimbursement may adversely affect our liquidity, cash flows and results of operations45% rewritten
- 15Ongoing reimbursement rate reductions, pricing pressures from Third-Party Payers and managed care payers, and increasing payer consolidation could significantly impact revenue, reduce profitability, and concentrate financial dependence on a few large payersNew
- 16We face periodic reviews and billing audits by governmental and private payers, which could result in adverse findings that may negatively impact our business
- 17If any of our pharmacies fail to comply with the conditions of participation in the Medicare program, that pharmacy could be terminated from Medicare, which could adversely affect our consolidated financial statements
- 18Regulatory changes, increased scrutiny, or reclassification of our compounding practices as an FDA-regulated outsourcing facility could lead to costly compliance requirements, operational disruptions, and reputational harmNew
- 19Our existing indebtedness could adversely affect our business and growth prospects27% rewritten
- 20We may incur additional debt, which could increase the risks associated with our leverageNew
- 21We may not be able to generate sufficient cash flow to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under such indebtedness, which may not be successful
Risks Relating to Our Common Stock
- 22Provisions of our corporate governance documents could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management, even if it is beneficial to our stockholders
- 23Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us
- 24We cannot guarantee that our stock repurchase program will enhance long-term stockholder value51% rewritten
- 25Pending and future litigation could subject us to significant monetary damages and/or require us to change our business practices
- 26We may be subject to liability claims for damages and other expenses that are not covered by insurance
- 27Pressures relating to downturns in the economy could adversely affect our business and consolidated financial statements
- 28Pursuing acquisitions or strategic investments and alliances may expose us to integration challenges, valuation uncertainties, operational disruptions, and potential financial losses if these investments fail to deliver expected benefitsNew
- 29Our business depends upon our information systems. A cyber-attack, security breach or our inability to effectively integrate, manage and keep our information systems secure and operational could disrupt our operations
- 30Reliance on third-party hosting services exposes us to potential security breaches, service disruptions, and pricing changes that could negatively impact operations and financial performanceNew
- 31Failure to maintain effective internal control over our financial reporting could have an adverse effect on our ability to report our financial results on a timely and accurate basis
- 32Acts of God, such as major weather disturbances or other force majeure events, could disrupt our business
Other Option Care Health 10-Ks
- FY2024 10-K risk factors35 risks
Option Care Health relies heavily on managed care payers for 88 percent of revenue and three vendors for 58 percent of supplies. The company carries $1,131.6 million in debt and faces extensive healthcare regulatory and reimbursement scrutiny.
Filed Feb 26, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.